Evidence map›Paper›PMID 39855300›Full record

ArticleThe American journal of pathology2025

Piezo2 Is a Key Mechanoreceptor in Lung Fibrosis that Drives Myofibroblast Differentiation.

Margaret A T Freeberg, Sarah V Camus, Valentina Robila, Apostolos Perelas, Thomas H Thatcher, Patricia J Sime

Abstract read
In one paragraph

Article in The American journal of pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Mechanobiology and Resolution of Lung Fibrosis.Annual review of physiology · 2026
    Review
  5. The importance of mechanical forces in chronic respiratory diseases.European respiratory review : an official journal of the European Respiratory Society · 2026
    Review
  6. Article
  7. PIEZO2 in tumors: from mechanobiological switches to activity-targeted therapies.Journal of experimental & clinical cancer research : CR · 2025
    Review
  8. Pulmonary Fibrosis-Focusing on the Future: Aspen Lung Conference 2024 Summary.American journal of respiratory cell and molecular biology · 2025
    Article
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Margaret A T FreebergDivision of Pulmonary Disease and Critical Care Medicine, Virginia Commonwealth University, Richmond, Virginia.
Sarah V CamusDivision of Pulmonary Disease and Critical Care Medicine, Virginia Commonwealth University, Richmond, Virginia.
Valentina RobilaDepartment of Pathology, Virginia Commonwealth University, Richmond, Virginia.
Apostolos PerelasDivision of Pulmonary Disease and Critical Care Medicine, Virginia Commonwealth University, Richmond, Virginia.
Thomas H ThatcherDivision of Pulmonary Disease and Critical Care Medicine, Virginia Commonwealth University, Richmond, Virginia.
Patricia J SimeDivision of Pulmonary Disease and Critical Care Medicine, Virginia Commonwealth University, Richmond, Virginia. Electronic address: patricia.sime@vcuhealth.org.

Funding

R01 Transfer from U. of Rochester- Lactate Promotes Scarring After IrradiationR01HL127001 · NHLBI · VIRGINIA COMMONWEALTH UNIVERSITY · PI SIME, PATRICIA JANET, WILLIAMS, JACQUELINE PATRICIA · 2016 to 2019
$1.5M
Mechanotransduction regulation of cellular metabolism in pulmonary fibrosisK99HL169903 · NHLBI · VIRGINIA COMMONWEALTH UNIVERSITY · PI THOMAS FREEBERG, MARGARET · 2024 to 2024
$171k
Pathways to FibrosisR03HL095402 · NHLBI · UNIVERSITY OF ROCHESTER · PI PHIPPS, RICHARD P., SIME, PATRICIA JANET · 2008 to 2009
$154k
Tissue stiffness promotes pro-fibrotic metabolic dysregulation in lung fibrosisF32HL154525 · NHLBI · VIRGINIA COMMONWEALTH UNIVERSITY · PI THOMAS FREEBERG, MARGARET · 2020 to 2022
$140k
NHLBI NIH HHS F32 HL154525NHLBI NIH HHS K99 HL169903NHLBI NIH HHS R01 HL127001NHLBI NIH HHS R03 HL095402
6 · The paper itself

Abstract

Idiopathic pulmonary fibrosis (IPF) and other progressive fibrotic interstitial lung diseases have limited treatment options. Fibroblasts are key effector cells that sense matrix stiffness through conformation changes in mechanically sensitive receptors, leading to activation of downstream profibrotic pathways. Here, the role of Piezo2, a mechanosensitive ion channel, in human and mouse lung fibrosis, and its function in myofibroblast differentiation in primary human lung fibroblasts (HLFs) was investigated. Human samples from patients with IPF and mouse tissue from bleomycin-induced pulmonary fibrosis were assessed. Primary HLFs from nonfibrotic donors were grown on substrates of different stiffness to induce myofibroblast differentiation and treated with a Piezo2 inhibitor. Piezo2 expression was up-regulated in tissue from patients with IPF and in fibrotic mouse lung tissue. Additionally, analysis of published single-cell RNA-sequencing data showed that Piezo2 was expressed in the profibrotic collagen triple helix repeat containing 1 (Cthrc1)

Indexed as

Cell DifferentiationIdiopathic Pulmonary FibrosisIon ChannelsMechanotransduction, CellularMyofibroblastsPulmonary FibrosisAnimalsBleomycinCells, CulturedFibroblastsHumansLungMaleMiceMice, Inbred C57BLBleomycinIon ChannelsPIEZO2 protein, humanPiezo2 protein, mouse

Identifiers

PMID39855300
PMCPMC11959423

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.